Core Insights - MBX Biosciences, Inc. is participating in the Stifel 2025 Virtual Cardiometabolic Forum, highlighting its focus on precision peptide therapies for endocrine and metabolic disorders [1][2] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company based in Carmel, Indiana, specializing in the discovery and development of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - Additionally, MBX has an obesity portfolio that includes MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [3]
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum